Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs

Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Share

Program Content

Activities

  • Current Management and Potential Role of HIF-PHIs
    Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 16, 2022

    Expires: November 16, 2023

Faculty

cover img faculity

Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Professor of Medicine
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Co Center-Director, IMPACT Center at JHU
(Improving Participation Among Diverse Populations in Cardiovascular Clinical Trials)
Co-Editor in Chief
American Journal of Preventive Cardiology
Baltimore, Maryland

cover img faculity

Matthew Weir, MD

Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, MD

Provided by

ProCE Banner
ProCE Banner

Jointly provided by USFH and Rockpointe

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline